Press Release Aug 27 2024
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing the receipt of final approval from the USFDA for Amantadine extended-release capsules in two dosages. The approval allows Zydus to market the drug, which is used for treating dyskinesia in Parkinson's disease patients. Additionally, Zydus is eligible for a period of exclusivity for the lower dosage of the drug.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
In the deck
Earlier from Zydus Lifesciences
- Press Release Aug 23 2024
- Press Release Aug 09 2024
- Press Release Jul 31 2024
- Press Release Jul 23 2024
- Press Release Jul 22 2024
Later from Zydus Lifesciences
- Press Release Aug 30 2024
- Zydus receives final approval from USFDA for Scopolamine Transdermal System 1 mg/3 days
- Press Release Sep 10 2024
- Press Release Sep 13 2024
- Press Release Sep 27 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences